This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2023.
Program Description
The prognosis of patients with diffuse large B-cell lymphoma (DLBCL) who do not respond to R-CHOP is poor, especially for those with relapsed or refractory (R/R) disease. In recent years, several novel therapeutic modalities for patients with R/R DLBCL have emerged with promising efficacy, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, and several are recommended by guidelines. This program will differentiate the novel mechanisms of action and administration requirements of these emerging antibody-based treatments and their place in therapy for patients with R/R DLBCL. Panelists will present patient cases outlining best practices for treatment selection and sequencing of antibody-based therapies.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 14, 2023
Expiration date: April 14, 2024
Time to complete activity: 1.0 hour
Learner level: Advanced
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the results of recent literature exploring novel chemotherapy-free regimens for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
- Analyze the differences between antibody-based therapies and chimeric antigen receptor T-cell therapy and how these treatment options can be incorporated into clinical practice
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
